Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Effective treatment and management of myelofibrosis requires a multidisciplinary approach that balances disease control with quality of life. This page is designed for international patients and their families who are seeking clear, evidence‑based information about the therapeutic pathways available at Liv Hospital. Myelofibrosis, a rare bone‑marrow disorder, affects approximately 1‑2 per 100,000 people worldwide, and advances in therapy now offer hope for prolonged survival and symptom relief. Below you will find an overview of disease understanding, therapeutic goals, medication choices, transplant possibilities, supportive strategies, and personalized monitoring plans—all tailored to the needs of patients traveling for care.
Our clinicians combine international best practices with state‑of‑the‑art facilities, ensuring that every step of your treatment and management journey is coordinated, compassionate, and aligned with your personal health goals. Whether you are newly diagnosed or have progressed despite prior therapy, the options outlined here can help you and your care team make informed decisions.
Myelofibrosis is a chronic myeloproliferative neoplasm characterized by the replacement of healthy bone‑marrow tissue with fibrous scar tissue. This process leads to anemia, splenomegaly, and a range of constitutional symptoms such as fatigue, night sweats, and weight loss. The disease can arise de novo (primary myelofibrosis) or evolve from other conditions like polycythemia vera or essential thrombocythemia.
Key clinical features include:
Prognostic scoring systems—such as the Dynamic International Prognostic Scoring System (DIPSS‑plus)—help clinicians estimate disease trajectory and guide therapeutic intensity. Understanding where a patient falls on this spectrum is essential for designing an individualized treatment and management plan that balances efficacy with tolerability.
The overarching objectives of treatment and management are threefold: alleviate symptoms, modify disease biology, and improve overall survival. While a cure remains elusive for most patients, modern therapies aim to reduce spleen size, control blood counts, and prevent progression to blast phase.
Specific goals include:
These goals are pursued through a combination of pharmacologic agents, procedural interventions, and supportive care measures. The treatment plan is regularly reassessed based on response criteria, side‑effect profile, and evolving patient preferences.
JAK‑inhibitors have become the cornerstone of modern myelofibrosis therapy. Ruxolitinib, the first FDA‑approved JAK1/2 inhibitor, demonstrates significant spleen volume reduction and symptom improvement in the majority of treated patients. However, not all patients achieve optimal response, and resistance or intolerance may develop.
Beyond JAK inhibitors, novel agents such as BET inhibitors, BCL‑2 antagonists, and immunomodulatory drugs are under clinical investigation and may soon expand the therapeutic armamentarium. The choice of pharmacologic therapy is individualized, taking into account baseline blood counts, comorbidities, and prior treatment history. Regular monitoring of blood parameters and symptom scores ensures that the treatment and management strategy remains optimal.
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative approach for myelofibrosis. Advances in reduced‑intensity conditioning regimens have broadened eligibility to older patients and those with comorbidities, though transplant‑related mortality still poses a significant risk.
Key considerations for transplant candidacy include:
At Liv Hospital, the transplant team integrates pre‑transplant evaluation, conditioning protocol selection, and post‑transplant supportive care within a single coordinated pathway. Outcomes are monitored through engraftment kinetics, graft‑versus‑host disease (GVHD) prophylaxis, and long‑term disease surveillance. For patients who are not transplant candidates, the focus shifts to maximizing medical therapy and quality‑of‑life measures as part of a comprehensive treatment and management plan.
Effective supportive care is a vital component of myelofibrosis treatment and management, addressing both disease‑related and treatment‑related symptoms. A multidisciplinary team—including hematologists, palliative care specialists, nutritionists, and physiotherapists—collaborates to create individualized symptom‑control regimens.
Common supportive interventions include:
Psychosocial support, including counseling and patient support groups, is also emphasized, recognizing the emotional burden of a chronic hematologic disease. By integrating these measures, Liv Hospital ensures that each patient’s overall well‑being is addressed alongside disease‑directed therapy.
Ongoing monitoring is essential to evaluate response, detect complications early, and adjust the treatment and management strategy as needed. Standard follow‑up includes:
Personalized care plans are built using these data points, incorporating patient preferences, travel logistics, and the comprehensive services offered by Liv Hospital. Tele‑medicine follow‑up appointments, coordinated with local physicians, provide continuity of care after patients return to their home countries.
Liv Hospital is a JCI‑accredited, internationally recognized center offering a full spectrum of hematology services for myelofibrosis patients from around the world. Our multidisciplinary team combines expertise in advanced pharmacologic therapy, stem‑cell transplantation, and supportive care, all delivered within a patient‑centered framework that includes language interpreters, travel coordination, and comfortable accommodation. By choosing Liv Hospital, patients benefit from cutting‑edge treatments, personalized care pathways, and a seamless experience tailored to the needs of international visitors.
Ready to discuss your personalized myelofibrosis care plan? Contact Liv Hospital today to schedule a virtual consultation with our hematology specialists and start your journey toward improved health and quality of life.
Send us all your questions or requests, and our expert team will assist you.
Myelofibrosis treatment aims to alleviate the most burdensome symptoms such as fatigue, night sweats, and weight loss, while also targeting the underlying disease process. Therapies strive to shrink an enlarged spleen, improve blood counts, and delay or prevent transformation to acute leukemia. By achieving these objectives, patients experience better functional status and quality of life, which together contribute to longer survival. The treatment plan is regularly reassessed to balance efficacy with side‑effects.
Ruxolitinib, the first FDA‑approved JAK1/2 inhibitor, reduces spleen volume and improves symptoms in most patients. Fedratinib is used after Ruxolitinib failure, while Momelotinib may help anemia and Pacritinib is suited for low‑platelet patients. Beyond JAK inhibitors, clinical trials are evaluating BET inhibitors, BCL‑2 antagonists, and immunomodulatory drugs. Choice depends on blood counts, prior therapies, and comorbidities, and patients are monitored for thrombocytopenia, anemia, infections, and other adverse effects.
Transplantation remains the only potentially curative option for myelofibrosis. Candidates are typically identified using prognostic tools such as DIPSS‑plus; high‑risk scores prompt earlier referral. Eligibility also depends on age, performance status, donor availability, and disease control with JAK inhibitors before conditioning. Reduced‑intensity regimens have expanded eligibility to older or comorbid patients, but transplant‑related mortality and graft‑versus‑host disease remain significant risks that require careful counseling.
Supportive interventions include red blood cell and platelet transfusions, erythropoiesis‑stimulating agents, and, when necessary, splenectomy for refractory splenomegaly. Symptom‑targeted medications (antipyretics, anti‑emetics, sleep aids) and non‑pharmacologic measures such as nutrition counseling and physiotherapy combat fatigue and weight loss. A multidisciplinary team—hematologists, palliative specialists, nutritionists, and psychologists—provides comprehensive care, ensuring that both disease‑related and treatment‑related side effects are managed effectively.
During the initial phase of therapy, complete blood counts are obtained every 2–4 weeks to detect cytopenias or transfusion needs. Imaging (ultrasound or MRI) monitors spleen size, while bone‑marrow biopsies are performed if disease progression is suspected. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN‑SAF) captures patient‑reported outcomes. Liver and renal function tests, as well as infection surveillance, are also routine, allowing clinicians to adjust doses or switch therapies promptly.
Liv Hospital combines state‑of‑the‑art facilities with a team experienced in JAK‑inhibitor therapy, stem‑cell transplantation, and comprehensive supportive care. The center provides language interpreters, travel coordination, and comfortable accommodation, ensuring a seamless experience for patients traveling from abroad. Tele‑medicine follow‑up and coordinated care with local physicians further guarantee continuity after patients return home, making Liv Hospital a preferred destination for high‑quality myelofibrosis management.
BlogHematologyFeb 19, 2026A complete blood count is a common test to check overall health. It helps find issues like anemia, infectio...
BlogHematologyFeb 19, 2026Thin blood, also known as thrombocytopenia, happens when you have too few platelets. Platelets help your bl...
BlogHematologyFeb 19, 2026Hemophilia is a genetic disorder that makes it hard for the body to form blood clots. It affects people all...
BlogAnemiaFeb 19, 2026Are you always tired, dizzy, or have brittle nails? Poor iron absorption might be the reason. It’s a ...
BlogHematologyFeb 19, 2026The Rule of Three is key in hematology. It helps labs check if a complete blood count (CBC) is right. It sa...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
